PsychoGenics and AstraZeneca Enter Agreement to Identify New Treatments for Central Nervous System Disorders

Tarrytown, N.Y., August 30, 2009 - PsychoGenics Inc. and AstraZeneca have entered into a drug discovery and development agreement to identify compounds that are likely to be useful for the treatment of certain Central Nervous System (CNS) disorders. Under the agreement, PsychoGenics will use its proprietary drug discovery technologies to evaluate a number of AstraZeneca drug candidates for their potential to treat psychiatric disorders.Read More.

PsychoGenics Appoints David A. Lowe, as Chief Scientific Officer and Executive Vice President of Research and Development

TARRYTOWN, N.Y., August 10, 2009 – PsychoGenics Inc., announced the appointment of David A. Lowe, Ph.D., as Chief Scientific Officer (CSO) and Executive Vice President of Research and Development (EVP, R&D) Read More.